Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
Beam Therapeutics Is Maintained at Sector Perform by RBC Capital
Beam Stock Rebounds as Leerink Upgrades Despite Fatality in Gene Editing Trial
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views